Maplight Therapeutics Earns Buy Rating from Needham & Company

요약

“Needham & Company LLC initiated coverage on Maplight Therapeutics with a 'buy' rating and $37.00 price target”
“The price target suggests a potential 53.27% upside from the company's previous close”
“Multiple analysts have recently issued ratings, with average consensus of 'Moderate Buy' and target price of $32.67”

Debt low Cash good Valuation high Drawdown neutral Recent recovery

Maplight Therapeutics, Needham & Company로부터 매수 평가 받다
Needham & Company LLC, Maplight Therapeutics에 대한 커버리지를 시작하며 '매수' 평가와 $37.00 목표가 제시
목표가는 이전 종가 대비 53.27%의 상승 잠재력을 시사
다수 애널리스트들이 최근 평가를 내렸으며, 평균 합의는 '보통 매수'와 $32.67의 목표가

출처: MarketBeat
링크: https://www.marketbeat.com/instant-alerts/maplight-therapeutics-nasdaqmplt-earns-buy-rating-from-analysts-at-needham-company-llc-2026-04-08/#google_vignette

#google_vignette

소셜 공유 미리보기(OG) 전용 페이지입니다.